FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma October 14, 2020 GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... December 21, 2020 Today is Random Acts of Kindness Day February 17, 2021 ESMO Asia Congress 2024, Singapore, 6-8 December November 27, 2024 Load more HOT NEWS Dr Ian Walker on Smoking: ‘A political no-brainer’ Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear... Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... Could proton beam therapy improve throat cancer treatment?
